Eli Lilly And Company Patent Portfolio Statistics

Eli Lilly And Company

Profile Summary

This article summarizes the perfomance of the assignee in the recent years. The overall statistics for this portfolio help to analyze the areas where the assignee is performing well. The filing trend, perfomance across the tech centers and the perfomance of the recent applications has been mentioned below. All the stats are calculated based on the perfomance in USPTO.

How does the overall patent portfolio of Eli Lilly And Company look like?

Assignee Art Units
Total Applications: 2,219 1,708,942
Granted Patents: 1,367 885,833
Grant Index 77.94% 66.44%
Abandoned/Rejected Applications: 387 (22.06%) 447,505 (33.56%)
In-Process Applications: 462 375,604
Average Grant Time: 2.51 Years 2.7 Years
Average Office Actions: 1.28 1.66

Which Technology Area Eli Lilly And Company is filing most patents in? (Last 10 years)

Art Unit Definition Total Applications
1625 Organic Chemistry 223
1624 Organic Chemistry 183
1626 Organic Chemistry 174
1614 117
1654 Fermentation, Microbiology, Isolated and Recombinant Proteins/Enzymes 84

How many patents are Eli Lilly And Company filing every year?

Year Total Applications Predicted
2022 0* 451
2021 68* 493
2020 65 425
2019 55 55
2018 39
2017 37
2016 33
2015 34
2014 47
2013 43

*The drop in the number of applications filed in last two years compared to previous years is because applications can take up to 18 months to get published

Recently filed patent applications of Eli Lilly And Company in USPTO?

Publication number: US20220175891A1
Application number: 17/551,904

The present invention relates to pharmaceutical insulin compositions comprising insulin, a preservative, and at least one selected from the group consisting of aspirin, acetaminophen, dexamethasone, heparin, meloxicam, bromfenac sodium, salicylic acid; and the use of the compositions to treat diabetes.

Publication date: 2022-06-09
Applicant: Eli Lilly And Company
Inventors: Monica Rixman Swinney

Publication number: None
Application number: 17/619,289


Publication date:
Applicant: Eli Lilly And Company
Inventors: Allan Howard Wolpert

Publication number: US20220096751A1
Application number: 17/547,688

A medication delivery device having a lock element. The device is connectable to an electrical plug of a conduit. The device includes an external housing with an opening that ports to a plug receiving hollow within an interior volume. An electrical circuit connected to at least one of a rechargeable battery and a memory controller includes a connection element within the plug receiving hollow. The lock element travels within the plug receiving hollow when a dose delivery assembly of the device operates for forcing medication from the device. The lock element is sized and positioned to have its travel halted by abutment with the plug, when the plug is within the plug receiving hollow and electrically interfacing with the connection element, to thereby halt the dose delivery assembly from further operating for forcing medication from the device.

Publication date: 2022-03-31
Applicant: Eli Lilly And Company
Inventors: Ann Kimberly Ringenberger

How are Eli Lilly And Company’s applications performing in USPTO?

Application Number Title Status Art Unit Examiner
17/551,904 Pharmaceutical Combinations Comprising Insulin And At Least An Agent Selected From Meloxicam, Bromfenac Sodium, Acetylsalicylic Acid, Salicyclic Acid And Paracetamol OPAP Central, Docket
17/619,289 Systems And Methods For Detecting Missed Bolus Doses Sent to Classification contractor
17/547,688 Medication Delivery Device With Mechanical Locking System Docketed New Case – Ready for Examination OPAP Central, Docket
17/535,059 Compounds And Methods Targeting Human Tau Docketed New Case – Ready for Examination OPAP Central, Docket
17/606,214 Method For Preparing Stable Peptide Formulations Docketed New Case – Ready for Examination OPAP Central, Docket